Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy (American Journal of Psychiatry (April 1, 2008) DOI: 10.1176/appi.ajp.2007.07060879);Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy

American Journal of Psychiatry

Volumn 165, Issue 6, 2008, Pages 749-752

  Einarson, Adrienne ^a   Pistelli, Alessandra ^b   DeSantis, Marco ^b   Malm, Heli ^b   Paulus, Wolfgang D ^b   Panchaud, Alice ^b   Kennedy, Debra ^b   Einarson, Thomas R ^b   Koren, Gideon ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE;

ARTICLE; CARDIOVASCULAR MALFORMATION; CONTROLLED STUDY; DATA BASE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MEDICAL LITERATURE; NEWBORN; PREGNANCY OUTCOME; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TERATOLOGY;

EID: 44949160055     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.2007.07060879     Document Type: Erratum

References (29)

1. Einarson TR, Einarson A: Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005; 14:823-827
2. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, Walker M: Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194:961-966
3. Malm H, Klaukka T, Neuvonen PJ: Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106:1289-1296
4. GlaxoSmithKline: Epidemiology study: paroxetine in the first trimester and the prevalence of congenital malformations. http://ctr.gsk.co.uk/Summary/ paroxetine/studylist.asp
5. Cole JA, Ephross SA, Cosmatos IS, Walker AM: Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16:1075-1085
6. Källén BA, Olausson P: Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007; 79:301-308
7. Diav-Citrin O, Shechtman S, Weinbaum D, Arnon J, Di Gianantonio E, Clementi M, Ornoy A: Paroxetine and fluoxetine in pregnancy: controlled study (abstract). Reprod Toxicol 2005; 20:459
8. Health Canada: Public advisory: Health Canada endorsed important safety information on Paxil (paroxetine), Oct 6, 2005. http://www.hc-sc.gc.ca/dhp-mps/ medeff/advisories-avis/public/2005/paxil_3_pa-ap_e.html
9. US Food and Drug Administration: FDA Public Health Advisory: Paroxetine. Dec 8, 2005. http://www.fda.gov/cder/drug/advisory/paroxetine200512.htm
10. American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice: ACOG Committee Opinion No 354: Treatment with selective serotonin reuptake inhibitors during pregnancy. Obstet Gynecol 2006; 108:1601-1603
11. Paxil, pregnancy, and birth defects. Nov 9, 2006. www. lawyersandsettlements.com/articles/paxil-pregnancy-birth-defects
12. Finer LB, Henshaw SK: Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006; 38:90-96
13. Einarson A, Selby P, Koren G: Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001; 26:44-48
14. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN: Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295:499-507
15. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Donnenfeld A, McCormak M, Leen-Mitchell M, Woodland C, Gardner A, Hom M, Koren G: Pregnancy outcome following first trimester exposure to fluoxetine. JAMA 1993; 269:2246-2248
16. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, Koren G: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279:609-610
17. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, Mastroiacovo Po, Addis A, Matsui D, Schuler L, Einarson TR, Koren G: Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001; 158:1728-1730
18. Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, Koren G: A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 2003; 48:106-110
19. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, Shakir S, Einarson A: Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005; 192:932-936
20. Djulus J, Koren G, Einarson TR, Wilton L, Shakir S, Diav-Citrin O, Kennedy D, Voyer Lavigne S, De Santis M, Einarson A: Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006; 67:1280-1284
21. Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD: The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998; 105:882-889
22. Malm H, Klaukka T, Neuvonen PJ: Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106:1289-1296
23. Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, Lipworth L, Sorensen HT: Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006; 17:701-704
24. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, Walker M: Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194:961-966
25. Hoffman JI, Kaplan S: The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39:1890-1900
26. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D: First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80:18-27
27. Einarson A, Schachtschneider AK, Halil R, Bollano E, Koren G: SSRI's and other antidepressant use during pregnancy and potential neonatal adverse effects: impact of a public health advisory and subsequent reports in the news media. BMC Pregnancy Childbirth 2005; 5:11
28. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G: Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49:726-735
29. Beck CT, Records K, Rice M: Further development of the Postpartum Depression Predictors Inventory - Revised. J Obstet Gynecol Neonatal Nurs 2006; 35:735-745